<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448317</url>
  </required_header>
  <id_info>
    <org_study_id>TDU12190</org_study_id>
    <secondary_id>U1111-1118-1213</secondary_id>
    <nct_id>NCT01448317</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered SAR236553 in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the safety and tolerability of ascending single doses of subcutaneously (SC)
      administered alirocumab (SAR236553/REGN727) in Japanese healthy male subjects.

      Secondary Objectives:

        -  To assess the pharmacodynamics effect of a single SC dose of alirocumab on serum
           low-density lipoprotein cholesterol (LDL-C) and other lipids and apolipoproteins such as
           total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density
           lipoprotein cholesterol, very low-density lipoprotein cholesterol, Triglycerides,
           Apolipoprotein B, Apolipoprotein A1 and Lipoprotein(a).

        -  To assess the Pharmacokinetic profile of a single SC dose of alirocumab.

        -  To assess the immunogenicity of a single SC dose of alirocumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4 sequential dose cohorts. Single dose followed by a total observation period of 15 weeks
      (106 days) for each participant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>106 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum Low-Density Lipoprotein Cholesterol (LDL-C) from baseline to each visit.</measure>
    <time_frame>106 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ApolipoproteinB, ApolipoproteinA1 and Lipoprotein(a) from baseline to each visit.</measure>
    <time_frame>106 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol (T-C), High-Density Lipoprotein Cholesterol (HDL-C), Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Triglycerides (TG) from baseline to each visit.</measure>
    <time_frame>106 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab dose 4 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab (Solution)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>SAR236553</other_name>
    <other_name>REGN727</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab (Lyophilized formulation)</intervention_name>
    <description>Pharmaceutical form: lyophilized formulation
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>SAR236553</other_name>
    <other_name>REGN727</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Solution)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Lyophilized formulation)</intervention_name>
    <description>Pharmaceutical form: lyophilized formulation
Route of administration: Subcutaneous</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject, between 20 and 65 years inclusive.

          -  Body weight between 50.0 and 95.0 kg inclusive, body mass index between 18.0 and 30.0
             kg/mÂ² inclusive.

          -  Serum LDL-C levels &gt;100 mg/dL

        Exclusion Criteria:

          -  Subject indicated for the use of statins according to criteria in Adult Treatment
             Panel (ATP) III Guidelines as updated in 2004

          -  Significant concomitant illness or history of significant illness such as cardiac,
             renal, neurological, endocrinological, dermatological, metabolic or lymphatic disease,
             or any other illness or condition that would adversely affect the subject's
             participation in this study.

          -  History or presence of drug or alcohol abuse

          -  Smoking more than 5 cigarettes or equivalent in any 24 hour period.

          -  Any medication (including St John's Wort) within 14 days before the inclusion or
             within 5 times the elimination half-life or pharmacodynamic (PD) half-life of that
             drug, whichever the longest; any vaccination within the last 28 days.

          -  Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen,
             anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV)
             antibodies, human immunodeficiency virus (HIV) antigen and antibodies, syphilis.

          -  Elevated cholesterol due to a secondary cause such as hypothyroidism or alcohol.

          -  Presence or history of drug hypersensitivity

          -  Initiation of a new exercise routine or major change to a previous exercise routine
             within 4 weeks prior to Screening.

          -  Initiation of a new diet or major change to a previous diet within 4 weeks prior to
             Screening.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016 Jul 1;118(1):56-63. doi: 10.1016/j.amjcard.2016.04.011. Epub 2016 Apr 21.</citation>
    <PMID>27184170</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

